Abstract

Embodiments of the present disclosure concern administration of a cell population to an individual for regeneration of a tissue. The cell population may comprise fibroblasts and/or immune cells, either of which may be modified or unmodified. The tissue for regeneration may be a thymus.

IPC Classes  ?

• A61K 35/33 - Fibroblasts
• A61K 40/00 - Cellular immunotherapy
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions for transport and reduces damage to cells in the organoids compared to known media. The organoids may be utilized for extended release of the fibroblasts for cell therapy and also for drug delivery at a target site following administration to an individual in need thereof.

IPC Classes  ?

• A61K 35/33 - Fibroblasts
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions for transport and reduces damage to cells in the organoids compared to known media. The organoids may be utilized for extended release of the fibroblasts for cell therapy and also for drug delivery at a target site following administration to an individual in need thereof.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/33 - Fibroblasts
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

Embodiments of the present disclosure concern administration of a cell population to an individual for regeneration of a tissue. The cell population may comprise fibroblasts and/or immune cells, either of which may be modified or unmodified. The tissue for regeneration may be a thymus.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• C07K 14/475 - Growth factorsGrowth regulators
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/18 - Growth factorsGrowth regulators

Abstract

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

IPC Classes  ?

• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61P 35/00 - Antineoplastic agents
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

IPC Classes  ?

• A61K 35/33 - Fibroblasts
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Embodiments of the disclosure concern methods and compositions related to cancer treatment for an individual utilizing recombinant fibroblast cells that comprise one or more activities that are endothelial cell-like. The cells are delivered to a tumor microenvironment following which their death results in destabilization of the tumor vasculature. In particular embodiments, the fibroblast cells recombinantly express one or more of ETV2, FOXC2, and FLI1.

IPC Classes  ?

• A61K 35/44 - VesselsVascular smooth muscle cellsEndothelial cellsEndothelial progenitor cells
• A61P 35/00 - Antineoplastic agents
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells